MPMarta Piksa

Marta Piksa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Piksa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding the role of membrane lipids in mechanism of antimicrobial photodynamic therapy in Escherichia coli

    by Marta Piksa, Mariusz A. Bromke, Carlos M. Marques, Sigolène Lecuyer, Patricia Daira, Baptiste Fourmaux, Ifor D. W. Samuel, Katarzyna Matczyszyn, Krzysztof J. Pawlik

    Antimicrobial photodynamic therapy (aPDT) is a promising alternative to antibiotics, yet the molecular factors determining bacterial susceptibility remain unclear. This study investigates the critical role of bacterial lipids, particularly cardiolipin (CL) in the aPDT response of Escherichia coli using methylene blue as a photosensitizer. Through genetic deletion (ΔclsABC) and chemical modification via mannitol supplementation, we demonstrate that reduced CL levels significantly enhance bacterial sensitivity, leading to an additional reduction in viability exceeding 3 log10. Quantitative lipidomics (MS,GC) confirmed substantial CL depletion and altered fatty acid saturation. Interestingly, while live CL-deficient cells were more vulnerable, biomimetic giant unilamellar vesicles (GUVs) with higher CL content showed greater susceptibility to photo-oxidation. These findings suggest that CL-rich microdomains in living bacteria act as functional scaffolds for stress-defense systems rather than mere targets for oxidative damage. Modulating membrane lipid composition thus represents a novel strategy to potentiate aPDT efficacy.

  • Top Cited Papers
    Open Access

    The role of the light source in antimicrobial photodynamic therapy

    by Marta Piksa, Cheng Lian, Imogen C. Samuel, Krzysztof J. Pawlik, Ifor D. W. Samuel, Katarzyna Matczyszyn

    Antimicrobial photodynamic therapy (APDT) is a promising approach to fight the growing problem of antimicrobial resistance that threatens health care, food security and agriculture. APDT uses light to excite a light-activated chemical (photosensitiser), leading to the generation of reactive oxygen species (ROS). Many APDT studies confirm its efficacy in vitro and in vivo against bacteria, fungi, viruses and parasites. However, the development of the field is focused on exploring potential targets and developing new photosensitisers. The role of light, a crucial element for ROS production, has been neglected. What are the main parameters essential for effective photosensitiser activation? Does an optimal light radiant exposure exist? And finally, which light source is best? Many reports have described the promising antibacterial effects of APDT in vitro, however, its application in vivo, especially in clinical settings remains very limited. The restricted availability may partially be due to a lack of standard conditions or protocols, arising from the diversity of selected photosensitising agents (PS), variable testing conditions including light sources used for PS activation and methods of measuring anti-bacterial activity and their effectiveness in treating bacterial infections. We thus sought to systematically review and examine the evidence from existing studies on APDT associated with the light source used. We show how the reduction of pathogens depends on the light source applied, radiant exposure and irradiance of light used, and type of pathogen, and so critically appraise the current state of development of APDT and areas to be addressed in future studies. We anticipate that further standardisation of the experimental conditions will help the field advance, and suggest key optical and biological parameters that should be reported in all APDT studies. More in vivo and clinical studies are needed and are expected to be facilitated by advances in light sources, leading to APDT becoming a sustainable, alternative therapeutic option for bacterial and other microbial infections in the future.